Everolimus (E) plus bevacizumab (B) is effective first-line treatment for patients (pts) with advanced renal cell carcinoma (RCC) with papillary features (PF): Results from a phase II trial Meeting Abstract
| Authors: | Feldman, D. R.; Lee, C. H.; Molina, A. M.; Knezevic, A.; Chen, Y.; Chaim, J.; Coskey, D. T.; Ged, Y.; Tickoo, S.; Reuter, V. E.; Patil, S.; Xiao, H.; Aghalar, J.; Apollo, A. J.; Carlo, M. I.; Motzer, R. J.; Voss, M. H. |
| Abstract Title: | Everolimus (E) plus bevacizumab (B) is effective first-line treatment for patients (pts) with advanced renal cell carcinoma (RCC) with papillary features (PF): Results from a phase II trial |
| Meeting Title: | 2018 Genitourinary Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 36 |
| Issue: | 6 Suppl. |
| Meeting Dates: | 2018 Feb 8-10 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2018-02-20 |
| Language: | English |
| ACCESSION: | WOS:000436179500621 |
| DOI: | 10.1200/JCO.2018.36.6_suppl.627 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 627 -- Source: Wos |
